Industry / Italy

State Pharmaceutical Spending Falls Again

May 2010 | Industry Trend Analysis

Printable version
Bookmark

BMI Core View: The introduction of government price erosion mechanisms will accelerate across

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Pharmaceuticals & Healthcare Industry To Be Impacted By EUR25bn (US$32bn) Austerity Package

Industry / Italy Silvio Berlusconi's government has won a confidence vote in the Senate over its EUR25bn (US$32bn) austerity package aimed at lowering the country's budget deficit from 5.3% of GDP in 2009 to 2.7% by 2012....

July 2010

Downward Pressure On Oncology Drugs

Industry / Italy In a move to control the rising costs of healthcare and public expenditure on medicines, the Italian government is to reduce the price of numerous oncology drugs in 2011. The has been made on the basis...

July 2010

Recordati Reports Positive Revenues

Industry / Italy Pharmaceutical company Recordati's consolidated revenues for the first nine months of 2009 were US$824.1mn, a 9.4% year-on-year (y-o-y) increase, of which pharmaceutical sales increased by 10.4% y-o-y...

October 2009

State Pharmaceutical Spending Rises In H109

Industry / Italy Pharmaceutical spending by the Italian National Health Service - the Servicio Sanitario Nazionale (SSN) - increased by +0.3% year-on-year (y-o-y) in the first half of 2009, according to the Association...

October 2009

Slow Market Growth Expected In The Medium Term

Industry / Italy BMI's proprietary Drug Expenditure Forecast Model reveals that the Italian pharmaceutical market will increase in value in 2009 (in local currency terms), after declining in the previous year. During...

October 2009